TG THERAPEUTICS, INC. Treasury Stock Acquired, Average Cost Per Share
TG THERAPEUTICS, INC. (TGTX) reported Treasury Stock Acquired, Average Cost Per Share of $28.55 per share for the 23-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:TreasuryStockAcquiredAverageCostPerShare · last filed 2026-08-05
- 2026-06-30: Treasury Stock Acquired, Average Cost Per Share 23 month $28.55.
- 2025-12-31: Treasury Stock Acquired, Average Cost Per Share 17 month $28.55.
- 2025-09-30: Treasury Stock Acquired, Average Cost Per Share 14 month $28.55.
| Period end | Treasury Stock Acquired, Average Cost Per Share 14 month | Treasury Stock Acquired, Average Cost Per Share 17 month | Treasury Stock Acquired, Average Cost Per Share 23 month |
|---|---|---|---|
| 2026-06-30 | $28.55 10-Q · filed 2026-08-05 | ||
| 2025-12-31 | $28.55 10-Q · filed 2026-05-06 | ||
| 2025-09-30 | $28.55 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |